CoChat

Efficacy of Octreotide-LAR in Dieting Women with Abdominal Obesity and Polycystic Ovary Syndrome

Open access
Gambineri, Alessandra, Patton, Laura, De Iasio, Rosaria, Cantelli, Barbara, Cognini, Graciela Estela, Filicori, Marco, Barreca, Antonina, Diamanti-Kandarakis, Evanthia, Pagotto, Uberto, Pasquali, Renato · 2005 · The Journal of Clinical Endocrinology & Metabolism
Cited by 47

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Context: Somatostatin reduces LH, GH, and insulin, and somatostatin receptors are present at the ovarian level; somatostatin analogs are thus potential candidates for treatment of the polycystic ovary syndrome (PCOS). Objective: The purpose of this study was to evaluate the effect of octreotide-LAR, a long-acting somatostatin analog, in anovulatory abdominal obese women with PCOS. Design: A single-blind, placebo-controlled study was performed, lasting for 7 months. Setting: The patients were ambulatory throughout the study. Patients: Twenty PCOS subjects were enrolled. Eighteen completed the study. Interventions: A low-calorie diet was given during the first month, a low-calorie diet plus octreotide-LAR (10 mg; n = 10 subjects) or placebo (n = 10 subjects) was then given, with one im injection every 28 d (for 6 months). Main Outcome Measures: The main outcome measures were clinical features, computerized tomography measurement of fat distribution, androgens, GH, IGF-I, IGF-binding proteins (IGFBPs), fasting and glucose-stimulated insulin, and ovulation. Results: Octreotide had no additional effect in reducing body fat or improving fat distribution than placebo. Conversely, octreotide produced an additional decrease in fasting (P = 0.018) and glucose-stimulated (P = 0.038) insulin levels, an increase in IGFBP-2 (P = 0.042) and IGFBP-3 (P = 0.047), and an improvement in hirsutism (P = 0.004). Moreover, a trend toward greater reductions in testosterone (P = 0.061) and androstenedione (P = 0.069) was observed in women treated with octreotide-LAR compared with those given placebo. All women treated with octreotide ovulated at the end of the study compared with only one of those receiving placebo (P < 0.001). Conclusions: Octreotide-LAR may be usefully applied to hypocalorically dieting, abdominal obese PCOS women to improve hyperandrogenism and the insulin-IGF-I system. Restoration of ovulatory menstrual cycles appears to be another advantage of this treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2004-2490

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 31

  1. 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome., Hum Reprod, 19, 41, 10.1093/humrep/deh098 · DOI · Paper page
  2. Gambineri, 2002, Obesity and the polycystic ovary syndrome., Int J Obes Rel Metab Disord, 26, 883, 10.1038/sj.ijo.0801994 · DOI · Paper page
  3. Franks, 2003, Assessment and management of anovulatory infertility in polycystic ovary syndrome., Endocrinol Metab Clin North Am, 32, 639, 10.1016/S0889-8529(03)00044-6 · DOI
  4. Poretsky, 1999, The insulin-related ovarian regulatory system in health and disease., Endocr Rev, 20, 535, 10.1210/edrv.20.4.0374 · DOI · Paper page
  5. Morales, 1996, Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distintict features., J Clin Endocrinol Metab, 81, 2854
  6. Chiodera, 1986, Inhibition by somatostatin of LHRH-induced LH release in normal mestruating women., Gynecol Obstet Invest, 22, 17, 10.1159/000298884 · doi:10.1159/000298884
  7. Brazaan, 1973, Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone., Science, 179, 77, 10.1126/science.179.4068.77 · DOI · Paper page
  8. Hsu, 1991, Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the β-cell., J Biol Chem, 266, 837, 10.1016/S0021-9258(17)35249-3 · DOI · Paper page
  9. Patel, 1990, Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor protein., Metabolism, 39, 63, 10.1016/0026-0495(90)90214-W · doi:10.1016/0026-0495(90)90214-w
  10. Prevelic, 1990, Inhibitory effect of sandostatin on secretion of luteinizing hormone and ovarian steroids in polycystic ovary syndrome., Lancet, 336, 900, 10.1016/0140-6736(90)92270-R · DOI
  11. Prevelic, 1992, Effects of the somatostatin analogue, octreotide, in polycystic ovary syndrome., Metabolism, 41, 76, 10.1016/0026-0495(92)90036-A · doi:10.1016/0026-0495(92)90036-a
  12. Prevelic, 1995, The effects of the somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries., Hum Reprod, 10, 28, 10.1093/humrep/10.1.28 · doi:10.1093/humrep/10.1.28
  13. Morris, 1995, Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ovary syndrome., Fertil Steril, 63, 742, 10.1016/S0015-0282(16)57475-5 · DOI
  14. Fulghesu, 1995, Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease., Fertil Steril, 64, 703, 10.1016/S0015-0282(16)57842-X · DOI
  15. Morris, 1999, Octreotide is not useful for clomiphene citrate resistance in patients with polycystic ovary syndrome but may reduce the likelihood of ovarian hyperstimulation syndrome., Fertil Steril, 71, 452, 10.1016/S0015-0282(98)00475-0 · DOI
  16. Lidor, 1998, Combined somatostatin analog and follicle-stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment., Gynecol Endocrinol, 12, 97, 10.3109/09513599809024957 · DOI
  17. Ciotta, 1999, Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinemia or normoinsulinemia., Hum Reprod, 14, 2951, 10.1093/humrep/14.12.2951 · DOI
  18. Wenzl, 1996, Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease., Acta Obstet Gynecol Scand, 75, 298, 10.3109/00016349609047106 · doi:10.3109/00016349609047106
  19. Gillis, 1997, Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly., Drugs, 53, 681, 10.2165/00003495-199753040-00009 · DOI
  20. Nestler, 1998, Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome., N Engl J Med, 338, 1876, 10.1056/NEJM199806253382603 · DOI · Paper page
  21. Ferriman, 1961, Clinical assessment of body hair growth in women., J Clin Endocrinol Metab, 21, 1440, 10.1210/jcem-21-11-1440 · DOI · Paper page
  22. Hud, 1992, Prevalence and significance of acanthosis nigricans in an adult obese population., Arch Dermatol, 128, 941, 10.1001/archderm.1992.01680170073009 · doi:10.1001/archderm.1992.01680170073009 · Paper page
  23. Baecke, 1982, A short questionnaire for the measurement of habitual physical activity in epidemiological studies., Am J Clin Nutr, 36, 939, 10.1093/ajcn/36.5.936 · DOI · Paper page
  24. Pasquali, 1999, The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment., Clin Endocrinol (Oxf), 50, 517, 10.1046/j.1365-2265.1999.00701.x · DOI · Paper page
  25. Garrone, 2002, Increased insulin-like growth factor (IGF)-II and IGF/IGF-binding protein ratio in prepubertal constitutionally tall children., J Clin Endocrinol Metab, 87, 5455, 10.1210/jc.2002-020614 · DOI
  26. Pagotto, 2002, Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels., J Clin Endocrinol Metab, 87, 5625, 10.1210/jc.2002-020776 · DOI · Paper page
  27. Vermeulen, 1999, A critical evaluation of simple methods for the estimation of free testosterone in serum., J Clin Endocrinol Metab, 84, 3666, 10.1210/jcem.84.10.6079 · DOI · Paper page
  28. Matsuda, 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing., Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462 · DOI · Paper page
  29. Bertoli, 1996, Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity., Horm Res, 49, 17
  30. Barkan, 2003, Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels., J Clin Endocrinol Metab, 88, 2180, 10.1210/jc.2002-021169 · DOI · Paper page
  31. Pawelezyk, 1993, Sandostatin has no direct effect on ovarian steroidogenesis in vitro., Hum Reprod, 8, 346

Cited by

See all 47

Metadata

Authors
Gambineri, A., Patton, L., De Iasio, R., Cantelli, B., Cognini, G. E., Filicori, M., Barreca, A., Diamanti-Kandarakis, E., Pagotto, U., & Pasquali, R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2005-07-01
Volume
90
Issue
7
Pages
3854-3862
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2006659599
Cited by
47
References
6
FWCI
5.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Octreotide-LAR in Dieting Women with Abdominal Obesity and Polycystic Ovary Syndrome. https://app.cochat.ai/papers/10.1210/jc.2004-2490
The paper
Gambineri, A., Patton, L., De Iasio, R., Cantelli, B., Cognini, G. E., Filicori, M., Barreca, A., Diamanti-Kandarakis, E., Pagotto, U., & Pasquali, R. (2005). Efficacy of Octreotide-LAR in Dieting Women with Abdominal Obesity and Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2004-2490

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.